U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C23H27FN4O3
Molecular Weight 426.4848
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PALIPERIDONE

SMILES

Cc1c(CCN2CCC(CC2)c3c4ccc(cc4on3)F)c(=O)n5CCCC(c5n1)O

InChI

InChIKey=PMXMIIMHBWHSKN-UHFFFAOYSA-N
InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3

HIDE SMILES / InChI
Molecular Formula C23H27FN4O3
Molecular Weight 426.4848
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: description was created based on several sources, including http://dx.doi.org/10.4172/2161-1459.1000117

Paliperidone (9-OH-risperidone) is the primary active metabolite of the older antipsychotic risperidone. While its specific mechanism of action is unknown, it is believed that paliperidone and risperidone act via similar if not the same pathways. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. Very common adverse effects are: headache, tachycardia, somnolence and insomnia.

CNS Activity

CNS Penetrant
2344
Curator's Comment:: Due to a hydroxyl group in position 9, paliperidone is less lipophilic than risperidone and crosses the blood-brain barrier less easily the parent drug. Experiments in knock-out mice have suggested that the brain entry of both risperidone and paliperidone may be limited by the presence in the blood-brain barrier of the P-glycoprotein, a multidrug efflux transporter, which has a slightly greater affinity for paliperidone than risperidone.

Originator

Approval Year

2006
175
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2575
Antagonist
2575
Antagonist
2575
Antagonist
2575
Blocker
511
 0.57 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8043
INVEGA

Approved Use

INVEGA SUSTENNA® (paliperidone palmitate) is indicated for the treatment of: Schizophrenia [see Clinical Studies 14.1

Launch Date

1.16648641E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
10.1 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/26189570/
75 mg × eq single, intramuscular
dose: 75 mg × eq
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7.5 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20589922/
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
22.214 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/26189570/
75 mg × eq single, intramuscular
dose: 75 mg × eq
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
410 ng × h/mL
EXPERIMENT
https://www.researchgate.net/profile/An_Vermeulen/publication/267692020_Population_Pharmacokinetics_of_Paliperidone_ER_in_Healthy_Subjects_and_Patients_With_Schizophrenia/links/5493e2b40cf22d7925da3fa6/Population-Pharmacokinetics-of-Paliperidone-ER-in-Healthy-Subjects-and-Patients-With-Schizophrenia.pdf
6 mg 1 times / day steady-state, oral
dose: 6 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
257.3 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20589922/
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
44.9 day
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/26189570/
75 mg × eq single, intramuscular
dose: 75 mg × eq
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
22.8 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20589922/
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
23 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021999s018lbl.pdf
single, oral
 PALIPERIDONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
26%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021999s018lbl.pdf
single, oral
 PALIPERIDONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
unhealthy, 12
n = 1
Health Status: unhealthy
Condition: Developmental delay
Age Group: 12
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
Disc. AE: Lethargy, Tachycardia...
AEs leading to
discontinuation/dose reduction:
Lethargy
Tachycardia
Hypokalemia
Dyskinesia
Dystonia
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
252 mg single, oral
Overdose
Dose: 252 mg
Route: oral
Route: single
Dose: 252 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/31308582
Page: p.47
unhealthy, 16
n = 1
Health Status: unhealthy
Condition: Conduct disorder
Age Group: 16
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/31308582
Page: p.47
Disc. AE: Loss of consciousness...
AEs leading to
discontinuation/dose reduction:
Loss of consciousness
Sources:
https://pubmed.ncbi.nlm.nih.gov/31308582
Page: p.47
15 mg 1 times / day multiple, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24556260
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 30
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/24556260
DLT: Motor tic...
Dose limiting toxicities:
Motor tic
Sources:
https://pubmed.ncbi.nlm.nih.gov/24556260
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Disc. AE: Depressive symptom, Psychotic disorder...
AEs leading to
discontinuation/dose reduction:
Depressive symptom (0.9%)
Psychotic disorder (0.9%)
Anxiety (0.4%)
Insomnia (0.4%)
Agitation (0.4%)
Abnormal dreams (0.4%)
Libido decreased (0.4%)
Substance abuse (0.4%)
Suicidal ideation (0.4%)
Paranoid schizophrenia (0.4%)
Akathisia (0.9%)
Headache (0.9%)
Dystonia (0.4%)
Dizziness (0.4%)
Tardive dyskinesia (0.4%)
Dyskinesia (0.4%)
Oromandibular dystonia (0.4%)
Extrapyramidal disorder (0.4%)
Erectile dysfunction (0.9%)
Amenorrhea (0.4%)
Ejaculation failure (0.4%)
Galactorrhea (0.4%)
Gynecomastia (0.4%)
Injection site pain (0.9%)
Chest discomfort (0.4%)
Weight increased (0.9%)
Semen volume decreased (0.4%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 38
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
Disc. AE: Dyskinesia, Dystonia...
AEs leading to
discontinuation/dose reduction:
Dyskinesia
Dystonia
Tremor
Diaphoresis
Tachycardia
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
Disc. AE: Cerebrovascular disorder (NOS), Stroke...
AEs leading to
discontinuation/dose reduction:
Cerebrovascular disorder (NOS)
Stroke
Transient ischemic attack (grade 3-5)
Neuroleptic malignant syndrome
QT interval prolonged
Tardive dyskinesia
Hyperglycemia
Dyslipidemia
Weight gain
Hyperprolactinemia
Intestinal stricture NOS
Orthostatic hypotension
Syncope
Leukopenia
Neutropenia
Agranulocytosis
Cognitive impairment
Motor dysfunction NOS
Seizures
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
Disc. AE: Cerebrovascular disorder (NOS), Stroke...
AEs leading to
discontinuation/dose reduction:
Cerebrovascular disorder (NOS)
Stroke
Transient ischemic attack
Neuroleptic malignant syndrome
QT interval prolonged
Tardive dyskinesia
Hyperglycemia
Dyslipidemia
Weight gain
Hyperprolactinemia
Seizures
Orthostatic hypotension
Syncope
Leukopenia
Neutropenia
Agranulocytosis
Cognitive impairment
Motor dysfunction NOS
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
AEs

AEs

AESignificanceDosePopulation
Dyskinesia Disc. AE
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
unhealthy, 12
n = 1
Health Status: unhealthy
Condition: Developmental delay
Age Group: 12
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
Dystonia Disc. AE
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
unhealthy, 12
n = 1
Health Status: unhealthy
Condition: Developmental delay
Age Group: 12
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
Hypokalemia Disc. AE
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
unhealthy, 12
n = 1
Health Status: unhealthy
Condition: Developmental delay
Age Group: 12
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
Lethargy Disc. AE
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
unhealthy, 12
n = 1
Health Status: unhealthy
Condition: Developmental delay
Age Group: 12
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
Tachycardia Disc. AE
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
unhealthy, 12
n = 1
Health Status: unhealthy
Condition: Developmental delay
Age Group: 12
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
Loss of consciousness Disc. AE
252 mg single, oral
Overdose
Dose: 252 mg
Route: oral
Route: single
Dose: 252 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/31308582
Page: p.47
unhealthy, 16
n = 1
Health Status: unhealthy
Condition: Conduct disorder
Age Group: 16
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/31308582
Page: p.47
Motor tic DLT
15 mg 1 times / day multiple, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24556260
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 30
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/24556260
Abnormal dreams 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Agitation 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Amenorrhea 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Anxiety 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Chest discomfort 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Dizziness 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Dyskinesia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Dystonia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Ejaculation failure 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Extrapyramidal disorder 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Galactorrhea 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Gynecomastia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Insomnia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Libido decreased 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Oromandibular dystonia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Paranoid schizophrenia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Semen volume decreased 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Substance abuse 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Suicidal ideation 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Tardive dyskinesia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Akathisia 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Depressive symptom 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Erectile dysfunction 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Headache 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Injection site pain 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Psychotic disorder 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Weight increased 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources:
https://pubmed.ncbi.nlm.nih.gov/25938474
Page: p.565
Diaphoresis Disc. AE
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 38
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
Dyskinesia Disc. AE
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 38
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
Dystonia Disc. AE
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 38
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
Tachycardia Disc. AE
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 38
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
Tremor Disc. AE
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 38
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/24580061
Page: p.210
Agranulocytosis Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
Cerebrovascular disorder (NOS) Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
Cognitive impairment Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
Dyslipidemia Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
Hyperglycemia Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
Hyperprolactinemia Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
Intestinal stricture NOS Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
Leukopenia Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
Motor dysfunction NOS Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
Neuroleptic malignant syndrome Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
Neutropenia Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
Orthostatic hypotension Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
QT interval prolonged Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
Seizures Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
Stroke Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
Syncope Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
Tardive dyskinesia Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
Weight gain Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
Transient ischemic attack grade 3-5
Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
Page: p.1
Agranulocytosis Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
Cerebrovascular disorder (NOS) Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
Cognitive impairment Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
Dyslipidemia Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
Hyperglycemia Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
Hyperprolactinemia Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
Leukopenia Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
Motor dysfunction NOS Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
Neuroleptic malignant syndrome Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
Neutropenia Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
Orthostatic hypotension Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
QT interval prolonged Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
Seizures Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
Stroke Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
Syncope Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
Tardive dyskinesia Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
Transient ischemic attack Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
Weight gain Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources:
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1601

inhibitor
1467
inhibitor
1604
substrate
1118

inhibitor
1702
inhibitor
1475

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1383

CYP2A6
627

CYP2C8
818

CYP4A
18

CYP2E1
790

P-gp
1330
UGT1A1
393

UGT1A6
289

BCRP
515

P-gp
1400
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2D6
1738
 no [IC50 61.9 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe detromethorphan
Page: 41, 81
CYP2A6
659
 no [Inhibition >30 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe coumarin
Page: 41, 81
CYP2E1
871
 no [Inhibition >30 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe chlorzoxazone
Page: 41, 81
CYP4A
29
 no [Inhibition >30 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe lauric acid
Page: 41, 81
CYP1A2
1532
 no [Inhibition >60 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe Caffeine
Page: 41, 81
CYP2C8
865
 no [Inhibition >60 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe phenytoin
Page: 41, 81
CYP2C9
1648
 no [Inhibition >60 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe phenytoin
Page: 41, 81
CYP3A4
1772
 no [Inhibition >60 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe testosterone
Page: 41, 81
P-gp
1514
 weak [IC50 63.26 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
BCRP
515
 yes
CYP2D6
1118
 yes
CYP3A4
1601
 yes
P-gp
1400
 yes
UGT1A1
393
 yes
UGT1A6
289
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1507
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY10226
https://www.001chemical.com/chem/144598-75-4
3B Scientific (Wuhan) Corp
3B3-032531
http://www.3bsc.com/index/pro_info.php?id=53795
AA Blocks
AA001JQR
https://www.aablocks.com/goods/Goods/detail?id=AA001JQR
AHH Chemical co.,ltd
MT-01921
http://www.ahhchemical.com/product/MT-01921.html
AK Scientific, Inc. (AKSCI)
J10457
http://www.aksci.com/item_detail.php?cat=J10457
AK Scientific, Inc. (AKSCI)
S451
http://www.aksci.com/item_detail.php?cat=S451
Aaron Chemicals
AR001KIJ
http://www.aaronchem.com/144598-75-4
AbMole Bioscience
M5848
http://www.abmole.com/products/paliperidone.html
Acadechem
ACDC-030009
http://acadechemical.com/product/1779
Aceschem
ACF023126
https://www.aceschem.com/catalog/144598-75-4.html
Achemo Scientific Limited
AC-64208
http://www.achemo.com/search/?Keyword= 144598-75-4
Achemtek
0102-022120
http://www.achemtek.com/144598-75-4
Acorn PharmaTech
ACN-050765
http://www.acornpharmatech.com/
Acros Organics
AC456250010
https://www.fishersci.com/shop/products/9-hydroxyrisperidone-98-acros-organics/AC456250010
Active Biopharma
ABP000395
http://www.activebiopharma.com/144598-75-4
Alfa Chemistry
AP1020719554
https://reagents.alfa-chemistry.com/product/9-hydroxyrisperidone-d4-solution-cas-1020719-55-4-756.html
Alsachim
1560
http://www.alsachim.com/product-C2633-glo.bal-view.html
Ambinter
Amb19132718
http://www.ambinter.com/reference/19132718
Angel Pharmatech
AG-11540
http://www.angelpharmatech.com/144598-75-4.html
Angene
AGN-PC-04XSV9
http://www.angenechemical.com/productshow/AGN-PC-04XSV9.html
Anward
ANW-42875
http://www.anward.com/pro_result/28250
Ark Pharm
AK-77508
http://www.arkpharminc.com/products/144598-75-4.html
Aurora Fine Chemicals LLC
A13.105.665
http://online.aurorafinechemicals.com/info?ID=A13.105.665
Aurum Pharmatech LLC
Q-4343
http://www.Aurumpharmatech.com/Product/ProductDetails/Q_4343
AvaChem Scientific
2244
http://www.avachem.com/productSearch.asp?2244
BLD Pharm
BD111798
http://www.bldpharm.com/products/144598-75-4.html
BOC Sciences
130049-85-3
https://www.bocsci.com/r-9-hydroxy-risperidone-r-paliperidone-cas-130049-85-3-item-262137.html
BOC Sciences
147663-01-2
https://www.bocsci.com/s-9-hydroxy-risperidone-s-paliperidone-cas-147663-01-2-item-262138.html
BioChemPartner
BCP02338
http://www.biochempartner.com/144598-75-4-BCP02338
BioCrick
BCC3834
http://www.biocrick.com/Paliperidone-BCC3834.html
BioSynth
Q-101425
https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-101425.html
Boerchem
BC228519
http://www.boerchem.com/?product_38518.html
Boerchem
BC677689
http://www.boerchem.com/?product_42087.html
CSNpharm
CSN10189
https://www.csnpharm.com/products/paliperidone.html
Chem Scene
CS-0386
http://www.chemscene.com/144598-75-4.html
ChemMol
30108656
http://www.chemmol.com/chemmol/30108656.html
ChemMol
44008670
http://www.chemmol.com/chemmol/44008670.html
ChemMol
44009994
http://www.chemmol.com/chemmol/44009994.html
ChemMol
49400035
http://www.chemmol.com/chemmol/49400035.html
ChemMol
81412039
http://www.chemmol.com/chemmol/81412039.html
Chemenu
CM110058
http://www.chemenu.com/products/CM110058
Chemspace
CSSB00000693926
https://chem-space.com/CSSB00000693926
Clearsynth
CS-EB-01587
https://www.clearsynth.com/en/CSEB01587.html
Clearsynth
CS-ER-01579
https://www.clearsynth.com/en/CSER01579.html
Clearsynth
CS-O-02070
https://www.clearsynth.com/en/CSO02070.html
Combi-Blocks
OR-2275
http://www.combi-blocks.com/cgi-bin/find.cgi?OR-2275
Coresyn
CM14424
http://www.coresyn.com/Cas144598-75-4.html
DAOGE BIOPHARMA
DG21-12007
https://www.daogechem.com/product/144598-75-4.html
Finetech
FT-0670101
http://www.finetechnology-ind.com/prod/detail/pub/1020719-55-4.html
Finetech
FT-0670102
http://www.finetechnology-ind.com/prod/detail/pub/130049-85-3.html
Finetech
FT-0600425
http://www.finetechnology-ind.com/prod/detail/pub/144598-75-4.html
Fluoropharm
YF10040
http://www.fluoropharm.com/product/YF10040.html
Glentham Life Sciences
GP3914
http://www.glentham.com/products/product/GP3914/
Hello Bio
HB1798
https://www.hellobio.com/paliperidone.html
LGC Standards
LGCAMP0491.03-01
https://www.lgcstandards.com/US/en/p/LGCAMP0491.03-01
LGC Standards
LGCFOR0491.03
https://www.lgcstandards.com/US/en/p/LGCFOR0491.03
LGC Standards
MM0491.03
https://www.lgcstandards.com/US/en/p/MM0491.03
Lab Network
LN00188652
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00188652
Matrix Scientific
125342
https://www.matrixscientific.com/125342.html
MedChem Express
HY-A0019
https://www.medchemexpress.com/Paliperidone.html
MolPort
MolPort-020-313-413
https://www.molport.com/shop/molecule-link/MolPort-020-313-413
Molcore
MC10226
https://www.molcore.com/product/144598-75-4
MuseChem
A000313
https://www.musechem.com/product/A000313.html
OChem
22777
http://www.ocheminc.com/index.php?act=psearch&pid=598P754
Renno Tech
RL01805
http://www.rennotech.com/product_show.asp?id=2054
Shanghai Send Pharmaceutical Technology Co., Ltd
send21033
http://shsendpharm.com/
Sigma-Aldrich
H-076_CERILLIAN
https://www.sigmaaldrich.com/catalog/product/cerillian/h076?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
P0099_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/p0099?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
1491809_USP
https://www.sigmaaldrich.com/catalog/product/usp/1491809?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule
S538546
http://www.smolecule.com/products/s538546
Synblock Inc
PB27526
http://www.synblock.com/product/144598-75-4.html
TCI (Tokyo Chemical Industry)
P1897
http://www.tcichemicals.com/eshop/en/us/commodity/P1897/index.html
THE BioTek
bt-278646
https://www.thebiotek.com/product/inhibitors/bt-278646
THE BioTek
bt-318627
https://www.thebiotek.com/product/others/bt-318627
Tocris
4493
https://www.tocris.com/products/paliperidone_4493
VladaChem
VL281908-10MG
https://www.vladachem.com/product.php?products=144598-75-4
Yuhao Chemical
M0403394
http://www.chemyuhao.com/144598-75-4.html
abcr GmbH
AB457979
http://www.abcr.com/shop/en/AB457979
eNovation Chemicals
D522284
http://www.enovationchem.com/productDetails.asp?productID=D522284
iChemical
EBD54215
http://www.ichemical.com/products/144598-75-4.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule
MCULE-5597043685
https://mcule.com/MCULE-5597043685/
PubMed

PubMed

TitleDatePubMed
Forty years of antipsychotic Drug research--from haloperidol to paliperidone--with Dr. Paul Janssen.
2007
Paliperidone extended release.
2007
Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.
2007 Apr
Enantioselective analysis of the antipsychotic 9-hydroxyrisperidone, main metabolite of risperidone, by chiral capillary EKC using dual CDs.
2007 Aug
Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
2007 Dec 15
Possible neuroleptic malignant syndrome associated with paliperidone.
2007 Fall
Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability.
2007 Feb
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
2007 Jul
Molecule of the month. Paliperidone.
2007 Jun
Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection.
2007 Jun
Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS.
2007 Jun 1
Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients.
2007 Jun 30
Paliperidone (Invega) for schizophrenia.
2007 Mar 12
New drug for schizophrenia.
2007 Mar-Apr
New drugs: paliperidone, dasatinib, and decitabine.
2007 Mar-Apr
Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders.
2007 Mar-Apr
A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
2007 May
Paliperidone extended-release tablets: a new atypical antipsychotic.
2007 May
The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia.
2007 Nov
Paliperidone: a new extended-release oral atypical antipsychotic.
2007 Oct
Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue.
2007 Oct 15
A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.
2007 Sep
Analytical and semipreparative enantioseparation of 9-hydroxyrisperidone, the main metabolite of risperidone, using high-performance liquid chromatography and capillary electrophoresis. Validation and determination of enantiomeric purity.
2007 Sep 7
Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
2008
Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.
2008
New drug update: 2007.
2008 Apr
Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans.
2008 Apr
Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.
2008 Apr
Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
2008 Feb
Paliperidone-ER: first atypical antipsychotic with oral extended release formulation.
2008 Feb
Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
2008 Jan
Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone.
2008 Jan
Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine.
2008 Jul 1
Gateways to clinical trials. July-August 2008.
2008 Jul-Aug
Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials.
2008 Jun
Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions.
2008 Jun
Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.
2008 May
Paliperidone for treatment of schizophrenia.
2008 May
Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
2008 Nov
Apparent seizure and atrial fibrillation associated with paliperidone.
2008 Nov 15
Gateways to clinical trials.
2008 Oct
Antipsychotic drugs inhibit the function of breast cancer resistance protein.
2008 Oct
Paliperidone extended-release for the treatment of schizophrenia.
2008 Oct
ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.
2008 Oct
Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression.
2008 Oct 3
Choreatic symptoms during and after treatment with paliperidone and escitalopram.
2008 Sep
Secondary delusional parasitosis treated with paliperidone.
2009 Apr
Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists.
2009 Feb
Paliperidone suppresses the development of the aggressive phenotype in a developmentally sensitive animal model of escalated aggression.
2009 May
Effects of quetiapine, risperidone, 9-hydroxyrisperidone and ziprasidone on the survival of human neuronal and immune cells in vitro.
2010 Mar
Patents

Patents

20020146456
2

Sample Use Guides

In Vivo Use Guide
In adults is 6 mg administered once daily In adolescents 12-17 years of age is 3 mg administered once daily
Route of Administration: Oral
In Vitro Use Guide
Paliperidone has dual hyperprolactinemic actions in lactotrophs i) by preserving the coupling of spontaneous electrical activity and prolactin secretion in the presence of dopamine and ii) by inhibiting intrinsic dopamine receptor activity in the absence of dopamine, leading to enhanced calcium signaling and secretion.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:37:23 UTC 2021
Edited
by admin
on Fri Jun 25 20:37:23 UTC 2021
Record UNII
838F01T721
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PALIPERIDONE
EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
PALIPERIDONE [USAN]
Common Name English
4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE, 3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)ETHYL)-6,7,8,9-TETRAHYDRO-9-HYDROXY-2-METHYL-
Systematic Name English
3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)ETHYL)-6,7,8,9-TETRAHYDRO-9-HYDROXY-2-METHYL-4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE
Systematic Name English
PALIPERIDONE [USP MONOGRAPH]
Common Name English
PALIPERIDONE [MART.]
Common Name English
PALIPERIDONE [EMA EPAR]
Common Name English
9-HYDROXYRISPERIDONE
Common Name English
RISPERIDONE SPECIFIED IMPURITY C [EP]
Common Name English
RO76477
Code English
PALIPERIDONE [WHO-DD]
Common Name English
PALIPERIDONE [INN]
Common Name English
PALIPERIDONE [VANDF]
Common Name English
(9RS)-3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)PIPERIDIN-1-YL))ETHYL)-9-HYDROXY-2-METHYL-6,7,8,9-TETRAHYDRO-4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE
Common Name English
NSC-759623
Code English
PALIPERIDONE [ORANGE BOOK]
Common Name English
PALIPERIDONE [USP-RS]
Common Name English
PALIPERIDONE [MI]
Common Name English
RISPERIDONE IMPURITY, 9-HYDROXYRISPERIDONE- [USP]
Common Name English
R-76477
Code English
RO-76477
Code English
PALIPERIDONE [JAN]
Common Name English
INVEGA
Brand Name English
Classification Tree Code System Code
WHO-ATC N05AX13
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
WHO-VATC QN05AX13
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
LIVERTOX 732
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
NDF-RT N0000175430
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
EMA ASSESSMENT REPORTS INVEGA (AUTHORIZED: PSYCHOTIC DISORDERS)
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
EMA ASSESSMENT REPORTS INVEGA (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
NCI_THESAURUS C66883
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
Code System Code Type Description
DRUG CENTRAL
4137
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
LACTMED
Paliperidone
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
ChEMBL
CHEMBL1621
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
EPA CompTox
144598-75-4
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
WIKIPEDIA
PALIPERIDONE
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
DRUG BANK
DB01267
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
INN
7977
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
USP_CATALOG
1491809
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY USP-RS
CAS
144598-75-4
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
IUPHAR
7258
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
PUBCHEM
115237
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
RXCUI
679314
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C66293
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
FDA UNII
838F01T721
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
EVMPD
SUB23268
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
MERCK INDEX
M8357
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY Merck Index
HSDB
8148
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
Related Record Type Details
MUSCARINIC ACETYLCHOLINE RECEPTOR M3
OFF TARGET->NON-INHIBITOR
NON-INHIBITOR
Ki
CYTOCHROME P450 2D6
METABOLIC ENZYME -> SUBSTRATE
HISTAMINE H1 RECEPTOR
TARGET -> INHIBITOR
INHIBITOR
Ki
ALPHA-1A ADRENERGIC RECEPTOR
TARGET -> INHIBITOR
INHIBITOR
Ki
MUSCARINIC ACETYLCHOLINE RECEPTOR M5
OFF TARGET->NON-INHIBITOR
NON-INHIBITOR
Ki
D(4) DOPAMINE RECEPTOR
TARGET -> INHIBITOR
INHIBITOR
Ki
ALPHA-2C ADRENERGIC RECEPTOR
TARGET -> INHIBITOR
INHIBITOR
Ki
Structure of PALIPERIDONE
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
5-HYDROXYTRYPTAMINE RECEPTOR 1D
TARGET -> INHIBITOR
INHIBITOR
Ki
HISTAMINE H2 RECEPTOR
TARGET->WEAK INHIBITOR
INHIBITOR
Ki
5-HYDROXYTRYPTAMINE RECEPTOR 2A
TARGET -> INHIBITOR
INHIBITOR
Ki
5-HYDROXYTRYPTAMINE RECEPTOR 1E
TARGET -> INHIBITOR
INHIBITOR
Ki
MUSCARINIC ACETYLCHOLINE RECEPTOR M4
OFF TARGET->NON-INHIBITOR
NON-INHIBITOR
Ki
D(2) DOPAMINE RECEPTOR
TARGET -> INHIBITOR
INHIBITOR
Ki
5-HYDROXYTRYPTAMINE RECEPTOR 5A
TARGET -> INHIBITOR
INHIBITOR
Ki
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
TRANSPORTER
IC50
MUSCARINIC ACETYLCHOLINE RECEPTOR M2
OFF TARGET->NON-INHIBITOR
NON-INHIBITOR
Ki
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
5-HYDROXYTRYPTAMINE RECEPTOR 4
TARGET -> INHIBITOR
INHIBITOR
Ki
ALPHA-2B ADRENERGIC RECEPTOR
TARGET -> INHIBITOR
INHIBITOR
Ki
5-HYDROXYTRYPTAMINE RECEPTOR 1A
TARGET -> INHIBITOR
INHIBITOR
Ki
D(1B) DOPAMINE RECEPTOR
TARGET -> INHIBITOR
INHIBITOR
Ki
MUSCARINIC ACETYLCHOLINE RECEPTOR M1
OFF TARGET->NON-INHIBITOR
NON-INHIBITOR
Ki
5-HYDROXYTRYPTAMINE RECEPTOR 7
TARGET -> INHIBITOR
INHIBITOR
Ki
5-HYDROXYTRYPTAMINE RECEPTOR 6
TARGET -> INHIBITOR
INHIBITOR
Ki
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
5-HYDROXYTRYPTAMINE RECEPTOR 1B
TARGET -> INHIBITOR
INHIBITOR
Ki
5-HYDROXYTRYPTAMINE RECEPTOR 2C
TARGET -> INHIBITOR
INHIBITOR
Ki
D(3) DOPAMINE RECEPTOR
TARGET -> INHIBITOR
INHIBITOR
Ki
Related Record Type Details
Structure of R-93725
METABOLITE -> PARENT
Trace in feces
URINE
Structure of R-84852
METABOLITE -> PARENT
FECAL
Structure of 9-KETO RISPERIDONE
METABOLITE -> PARENT
URINE
Structure of 3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)ETHYL)-6,7,8,9-TETRAHYDRO-2-METHYL-4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE
PARENT -> METABOLITE ACTIVE
MAJOR
PLASMA
Related Record Type Details
Structure of 3-(2-CHLOROETHYL)-2-METHYL-9-HYDROXY-6,7,8,9-TETRAHYDRO-4H-PYRIDO (1,2-A) PYRIMIDIN-4-ONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of R-84852
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of R-56109
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 9-KETO RISPERIDONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)ETHYL)-6,7,8,9-TETRAHYDRO-2-METHYL-4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE
PARENT -> IMPURITY
not more than the area of the principal peak in the chromatogram obtained with reference solution (b)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of PALIPERIDONE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
ORAL BIOAVAILABILITY PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966